Trevi Therapeutics (TRVI) Interest Coverage Ratio (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Interest Coverage Ratio of 61.91 for Q1 2026, up 1.56% year-over-year from 60.96 in Q1 2025, and down 257.51% quarter-over-quarter from 39.31 in Q4 2025.
Trevi Therapeutics (TRVI) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Interest Coverage Ratio history runs 9 years deep, the most recent figure standing at 61.91 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 1.56% year-over-year to 61.91; the TTM figure through Mar 2026 stood at 242.19 (up 21.23% YoY), while the FY2025 annual figure was 0.6, up 86.5% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 61.91, down from 39.31 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 159.52 in Q4 2023, with the low at 12243.0 in Q4 2024.
- The 5-year median for Interest Coverage Ratio is 26.51 (2022), against an average of 740.66.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio surged 1295.72% in 2023, then tumbled 7775.0% in 2024.
- Trevi Therapeutics' Interest Coverage Ratio stood at 13.34 in 2022, then soared by 1295.72% to 159.52 in 2023, then sank by 7775.0% to 12243.0 in 2024, then soared by 100.32% to 39.31 in 2025, then slumped by 257.51% to 61.91 in 2026.
- Business Quant data shows TRVI's Interest Coverage Ratio at 61.91 in Q1 2026, 39.31 in Q4 2025, and 14.85 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | -38.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.07 |
| Mar 31, 2026 | -61.91 |
| Dec 31, 2025 | 39.31 |
| Sep 30, 2025 | -14.85 |
| Jun 30, 2025 | -13.35 |
| Mar 31, 2025 | -62.90 |
| Dec 31, 2024 | -12,243.00 |
| Sep 30, 2024 | -65.22 |
| Jun 30, 2024 | -9.88 |
| Mar 31, 2024 | -8.37 |
| Dec 31, 2023 | 159.52 |
| Sep 30, 2023 | -131.09 |
| Jun 30, 2023 | -54.78 |
| Mar 31, 2023 | -32.74 |
| Dec 31, 2022 | -13.34 |
| Sep 30, 2022 | -28.78 |
| Jun 30, 2022 | -26.51 |
| Mar 31, 2022 | -23.26 |
| Dec 31, 2021 | 28.53 |
| Sep 30, 2021 | -22.93 |